Skip to main content
Premium Trial:

Request an Annual Quote

AmoyDx, Illumina Partner to Develop NGS Cancer Diagnostics for Chinese Clinical Oncology Market

NEW YORK (GenomeWeb) – Amoy Diagnostics of Xiamen, China, and Illumina are collaborating to develop next-generation sequencing cancer diagnostics for the Chinese clinical oncology market, the companies said yesterday.

Under the partnership, AmoyDx will develop and commercialize a series of cancer tests that use Illumina NGS technology, including the firm's TruSight Tumor 15 panel, which assesses 15 genes that are commonly mutated in solid tumors.

Amoy already offers genetic tests to detect mutations in cancer genes such as EGFR, KRAS, NRAS, and BRAF, as well as ALK and ROS-1 gene fusions, and several of these tests are approved by the China Food and Drug Administration. "However, as the number of clinically actionable gene variants in cancer increases, NGS technology is crucial in order for companion diagnostics to keep pace," said Limou Zheng, AmoyDx's CEO and president, in a statement.

Illumina Senior VP and Chief Medical Officer Rick Klausner said in the statement that working with firms such as Amoy "is central to Illumina's strategy to advance personalized cancer diagnostics globally."

AmoyDx offers a portfolio of molecular tests and runs a service center for oncology biomarker analysis. It is also a therapy diagnostics partner for several multinational pharmaceutical companies that offer targeted cancer therapies. The firm says it is the largest provider of molecular diagnostics products for personalized healthcare in China.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.